Sensitivity to carbonyl cyanide m-chlorophenylhydrazone (mCICCP); bcl-2, bax, and bcl-x expression; and p53 status in 16 samples from patients with acute myeloblastic leukemia
Patient no. . | mClCCP IC50 . | Mean bcl2 (BFM × 105) . | Mean bax (BFM × 106) . | Mean bcl-x (BFM × 105) . | p53 status . |
---|---|---|---|---|---|
154R | 6 | 3.1 | 2.7 | 6.1 | wt |
16 | 10 | 0.54 | 1.5 | 3.9 | wt |
161 | 2 | 0.81 | 1.2 | 3.4 | wt |
145 | 10 | 2.0 | 2.3 | 5.5 | wt |
139 | 4 | 0.98 | 0.5 | 2.4 | wt |
178 | 2 | 4.6 | 7.8 | 3.5 | wt |
179 | 2 | 1.4 | 2.2 | 2.1 | wt |
71 | 4 | 2.6 | 2.9 | Failed | wt |
177 | 4 | 1.4 | 1.8 | 2.9 | wt |
71 | 10 | 0.54 | 0.57 | 1.1 | 273cgt-cat |
136 | 7 | 0.29 | 0.16 | 0.91 | 249agg-tgg |
157 | 10 | 2.3 | 1.6 | 1.9 | 273cgt-cat |
95 | 1 | 0.66 | 0.43 | 1.8 | wt |
184 | 11 | 1.26 | 2.74 | 2.2 | Not done |
134 | 6 | 3.1 | 2.3 | 1.7 | Not done |
76 | 4 | 2.7 | 0.97 | 2.66 | Not done |
Patient no. . | mClCCP IC50 . | Mean bcl2 (BFM × 105) . | Mean bax (BFM × 106) . | Mean bcl-x (BFM × 105) . | p53 status . |
---|---|---|---|---|---|
154R | 6 | 3.1 | 2.7 | 6.1 | wt |
16 | 10 | 0.54 | 1.5 | 3.9 | wt |
161 | 2 | 0.81 | 1.2 | 3.4 | wt |
145 | 10 | 2.0 | 2.3 | 5.5 | wt |
139 | 4 | 0.98 | 0.5 | 2.4 | wt |
178 | 2 | 4.6 | 7.8 | 3.5 | wt |
179 | 2 | 1.4 | 2.2 | 2.1 | wt |
71 | 4 | 2.6 | 2.9 | Failed | wt |
177 | 4 | 1.4 | 1.8 | 2.9 | wt |
71 | 10 | 0.54 | 0.57 | 1.1 | 273cgt-cat |
136 | 7 | 0.29 | 0.16 | 0.91 | 249agg-tgg |
157 | 10 | 2.3 | 1.6 | 1.9 | 273cgt-cat |
95 | 1 | 0.66 | 0.43 | 1.8 | wt |
184 | 11 | 1.26 | 2.74 | 2.2 | Not done |
134 | 6 | 3.1 | 2.3 | 1.7 | Not done |
76 | 4 | 2.7 | 0.97 | 2.66 | Not done |
IC50 indicates the dose of mCICCP which induces 50% loss of mitochondrial membrane potential; BFM, bound fluorochrome molecules.
Correlation coefficients (Spearman ρ for mClCCP IC50 with bcl family expression) were −0.172 for bcl2, 0.178 for bax, and −0.282 for bcl-x; none of these correlations were significant at theP < .05 level.